On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Officer Presents Initial Findings from Analysis of Landmark UK 100,000 Genomes Project

  • Helomics chief technology officer speaks at inaugural UK 100,000 Genomes Project Conference
  • The 100,000 Genomes Project is a UK-government project, sequenced whole genomes from National Health Service patients
  • The depth of the project data is best in class, yielding useful benchmarks to help validate Helomics models

Dr. Mark Collins, chief technology officer of Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics subsidiary, recently spoke at the inaugural UK 100,000 Genomes Project Conference. Collins presented initial findings from Helomics’ analysis of UK 100,000 Genomes Project (“UK100K GP”) data toward Helomics’ goal of building AI-driven predictive models of ovarian cancer. The inaugural conference was hosted by Genomics England on November 4 in London.

According to Global Market Insights Inc., the precision medicine market is forecast to reach more than $96 billion by 2024. Helomics is an innovative precision-medicine company positioned for growth in this growing market. A subsidiary of Predictive Oncology, Helomics is dedicated to improving the standard of care for cancer patients by harnessing the power of a patient’s own living tumor to build multi-omics AI-driven predictive models of tumor drug response to improve clinical outcomes for patients

The 100,000 Genomes Project is a United Kingdom government endeavor that is sequencing whole genomes from National Health Service patients (http://ibn.fm/M9bGx). The project focuses on rare diseases, some common types of cancer and infectious diseases. Recruitment of participants to the 100,000 Genomes Project was completed in 2018, with the 100,000th sequence achieved in December 2018. The aim of the project is to transform health care through new diagnoses and personalized treatments.

Helomics partnered with the UK100K GP last year to bring its invaluable expertise and data to the groundbreaking research. The company is leveraging its proprietary, multi-omic database of tumor-drug-response profiles using the proven power of AI to build predictive models of ovarian cancer. The goal is for these AI-driven predictive models to be used by clinicians to individualize treatment options and by pharma researchers to develop new targeted therapies in the quest to improve outcomes for women with ovarian cancer.

“This partnership is key to our approach of building AI-driven predictive models,” said Collins. “We are delighted to participate in the scientific session, panel discussion and an invite-only session on the expansion of the UK 100,000 Genomes Project to 5 million genomes. The depth of both the genomic and clinical data for ovarian cancer from the project is best in class, yielding useful benchmarks to validate our models. Over the next year, we intend to explore additional projects to enable use of our AI-driven predictive models to improve outcomes for ovarian cancer patients in the UK, as well as seek partnerships with UK pharma companies for the development of new precision ovarian cancer therapies.”

In addition to speaking during the scientific session of the conference, Collins also participated in an invitation-only session focused on the expansion of the UK 100K GP to 5 million genomes.

Based in Eagan, Minnesota, Predictive Oncology operates through three business units: Helomics, TumorGenesis and Skyline Medical. Predictive Oncology works together with the pharmaceutical, diagnostic and biotechnology industries to develop highly customizable assessment methods that can lead to more effective treatments for patients. Predictive Oncology continues to take advantage of the synergies of its subsidiaries to bring precision medicine to the treatment of cancer. The company is at the vanguard of innovation in using AI in improving outcomes for cancer patients. For investors, Predictive Oncology offers the potential for significant ROI as it focuses on improving patient outcomes.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

May 22, 2020

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a […]

Rotate your device 90° to view site.